Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2012 / Article
Special Issue

The Potential Benefit of Complementary/Alternative Medicine in Cardiovascular Diseases

View this Special Issue

Review Article | Open Access

Volume 2012 |Article ID 873210 | https://doi.org/10.1155/2012/873210

Hong Jiang, Ashley C. Torregrossa, Deepa K. Parthasarathy, Nathan S. Bryan, "Natural Product Nitric Oxide Chemistry: New Activity of Old Medicines", Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 873210, 9 pages, 2012. https://doi.org/10.1155/2012/873210

Natural Product Nitric Oxide Chemistry: New Activity of Old Medicines

Academic Editor: Ka Kit Hui
Received14 Oct 2011
Accepted19 Jan 2012
Published02 Apr 2012


The use of complementary and alternative medicine (CAM) as a therapy and preventative care measure for cardiovascular diseases (CVD) may prove to be beneficial when used in conjunction with or in place of conventional medicine. However, the lack of understanding of a mechanism of action of many CAMs limits their use and acceptance in western medicine. We have recently recognized and characterized specific nitric oxide (NO) activity of select alternative and herbal medicines that may account for many of their reported health benefits. The ability of certain CAM to restore NO homeostasis both through enhancing endothelial production of NO and by providing a system for reducing nitrate and nitrite to NO as a compensatory pathway for repleting NO bioavailability may prove to be a safe and cost-effective strategy for combating CVD. We will review the current state of science behind NO activity of herbal medicines and their effects on CVD.

1. Introduction

Complementary and alternative medicine (CAM) is the term for medical products and practices that are not a part of standard care. There is generally a lack of understanding of their mechanisms of action and/or the active compounds. Rigorous, well-designed clinical trials for many CAM therapies are often lacking; therefore, the safety and effectiveness of many of these types of therapies are uncertain and as a result are not recognized as mainstream therapy. However, Traditional Chinese Medicine (TCM) is a form of CAM that remains the primary form of medicine throughout a large portion of Asia and Asian communities in the rest of world with a long history of safety and efficacy in a number of different diseases. In fact, one could argue that TCM is the earliest form of CAM. Defining CAM here in the USA is difficult because the field is very broad and constantly changing. The National Institutes of Health now has a dedicated Center for Complementary and Alternative Medicine (NCCAM) due to the growing popularity of such approaches to ensure safety and promote rigorous clinical trials to demonstrate efficacy. NCCAM defines CAM as a group of diverse medical and health care systems, practices, and products that are not generally considered part of conventional medicine, as practiced by medical doctors and their allied health professionals. The boundaries between CAM and conventional medicine are not absolute, and specific CAM practices may, over time, become widely accepted. Complementary medicine refers to use of alternative treatments together with conventional medicine, such as using acupuncture or herbal medicines in addition to usual care to help with disease management. Most use of CAM by Americans is complementary. Alternative medicine refers to use of CAM in place of conventional medicine. Integrative medicine combines treatments from conventional medicine and CAM for which there is some high-quality evidence of safety and effectiveness. It is also called integrated medicine. Since many CAM-based therapies are derived from TCM, we will provide a brief historical account behind the theory of TCM, and how this has now been integrated into CAM approaches here in the USA.

TCM has long been used as a major health care system in China and many other countries in Asia. Here in the USA, it is typically referred to as CAM. TCM has its origin in ancient Taoist philosophy, which views a person as an energy system in which the body, mind, and spirit are unified into one when in harmony and are disrupted in disease. TCM practice treats the patient as a whole, not as a part, and it emphasizes a holistic approach that attempts to bring the mind, body, and spirit into harmony. TCM theory is extremely complex and originated thousands of years ago through meticulous observation of nature, the cosmos, and the human body. In TCM theory, imbalance between yin and yang is a summation of all kinds of basic disease and disorders. There is a growing and sustained interest in CAM and TCM fueled by a combination of factors including recognition of the benefits, dissatisfaction with and ineffectiveness of traditional Western medicines, increasing commitment to holistic care, skepticism regarding adverse side effects of drugs, and increasing evidence for the personalized nature of various combinations of herbs for specific disorders [1]. The use of TCM is increasing in Western nations, mostly among people of Southeast Asian origin. Patients who use TCM in Western countries report that the main reason for using it is that TCM is a “more natural” and potentially safer alternative in the treatment of chronic illness than pharmaceutical drugs or surgery [1]. Of the approximately 500 herbs that are in use today, 50 or so are very commonly used alone or in combination. Rather than being prescribed individually, single herbs are combined into formulas that are designed to adapt to the specific needs of individual patients. A herbal formula can contain from 3 to 25 herbs. Each herb has one or more of the four flavors/functions and one of five “temperatures” “” (pronounced “chi”) (hot, warm, neutral, cool, cold). Herbal formulations work to balance the body from the inside out. Traditional herbal medicines include herbs, herbal materials, herbal preparations, and processed herbal products that contain parts of plants or other plant materials as active ingredients, which assist with strengthening the vital energies (chi), blood, and fluids internally. They are typically administered as tablets, pills, elixirs, soups, liquid extracts, and teas and broadly classified as dietary supplements here in the USA. There are a number of published reports on the association of TCM and NO-related effects [2, 3]. Recently, there are increased interests in the role for NO system in regulation of cardiovascular function by TCM used commonly for cardiovascular disorders. Recognizing and understanding NO activity of TCM may help explain centuries of treatment efficacy in a number of diseases and highlight new treatment options for conditions of NO insufficiency.

2. Current Global Markets for CAM

A 2002 survey of US adults 18 years and older conducted by the National Center for Health Statistics (CDC) and the NCCAM indicated that 74.6% had used some form of CAM, 62.1% had done so within the preceding 12 months, 54.9% used CAM in conjunction with conventional medicine, and 14.8% sought care from a licensed or certified practitioner suggesting that most individuals who use CAM prefer to treat themselves [4]. The industry of alternative and complementary medicines broadly classified as dietary supplements is expected to be $250 billion by 2016 worldwide. In 2004, a survey of nearly 1,400 US hospitals found that more than one in four offered alternative and complementary therapies such as acupuncture, homeopathy, and massage therapy. Herbal treatments are the most popular form of traditional medicine or CAM and are highly lucrative in the international marketplace. Annual revenues in Western Europe reached $5 billion in 2003-2004. In China, sales of products totaled $14 billion in 2005. Herbal medicine revenue in Brazil was $160 million in 2007, according to WHO Fact Sheet no. 134, 2008. Therefore, this industry and type of health care can no longer be ignored. In order to better understand the mechanism of action and the safety profile of herbal remedies, more research and resources are needed. Identifying physiological systems or molecular targets that may be affected by TCM will help propel the field and industry forward and create a better safety and efficacy profile of certain CAMs.

3. Production and Regulation of NO in the Cardiovascular System

Appropriate levels of NO production are critical in tissue blood perfusion and protection of cardiovascular tissues against ischemia and infarction. NO is endogenously generated from the amino acid L-arginine and molecular oxygen in reactions catalyzed by a family of enzymes called NO synthases (NOS). There are three mammalian NOS isoforms: neuronal (nNOS), endothelial (eNOS), and inducible (iNOS). They share 50–60% homology at the amino acid level [5]. Under physiological conditions, the dominant NOS isoform in the vasculature is eNOS, which rather than being a constitutive enzyme as was first suggested is dynamically regulated at the transcriptional, posttranscriptional, and posttranslational levels [6]. Endothelial dysfunction arises from downregulation of eNOS expression and activity and uncoupling of NOS generating free radicals [7]. We now recognize and appreciate that the endothelial production of NO declines progressively with age and can be further reduced by poor diet and lifestyle [810]. This becomes the basis for endothelial dysfunction and the etiology of a number of CVD-related symptoms. Restoring endogenous production of NO or providing an exogenous source of NO would be an attractive therapeutic option if this intervention could slow down the progression of endothelial dysfunction and reduce the risk of CVD.

Recently, an alternative pathway for NO generation was discovered, wherein the inorganic anions nitrate and nitrite, most often considered inert end products from NO oxidation, can be reduced back to NO and other bioactive nitrogen oxide species. This nitrate-nitrite-nitric oxide pathway is regulated differently than the classic L-arginine-nitric oxide synthase pathway as shown in Figure 1, and it is greatly enhanced during hypoxia and acidosis. Nitrite and nitrate have now moved to the forefront of NO biology [11] with the discovery that it represents a major storage form of NO in both blood and tissues [12]. Dietary nitrite and nitrate have been shown to protect from tissue injury and restore NO homeostasis in eNOS−/− mice [13, 14]. Orally administered nitrite also attenuates cardiac allograft rejection in rats [15]. Nitrate is the primary anion present in green leafy vegetables and has been hypothesized to account for some of the health benefits of vegetables [16]. There are a number of published studies to support this hypothesis via its reduction to nitrite [17, 18]. The nitrate-nitrite-nitric oxide pathway is boosted by dietary intake of nitrate. Dietary nitrate supplementation has been shown to reduce diastolic blood pressure [19], inhibit platelet aggregation, and protect the heart from ischemia-reperfusion injury [20]. This pathway may also explain the effects of certain ethnic diets. Dietary nitrate in Japanese food was shown to lower blood pressure in healthy volunteers [21]. It is well established that diets rich in fruit and vegetables (e.g., the Mediterranean diet) protect against development of cardiovascular disease [2224] and these data may provide evidence as to why.

The first metabolic activation step for this pathway requires commensal bacteria to reduce nitrate to nitrite [25]. There are a number of endogenous systems in mammals capable of reducing nitrite to NO although most are very inefficient and inhibited by oxygen [26]. For this system to proceed, there must be enough substrate for reduction and the necessary bacteria and reductive machinery to reduce nitrate all the way down to NO. Dietary and enzymatic sources of nitrate are a potentially large source of nitrite and ultimately NO in the human body. The nitrite converted from nitrate by oral bacteria disproportionates with formation of NO after entering the acidic environment of the stomach, helping to reduce gastrointestinal tract infection, increase mucous barrier thickness and increase gastric blood flow [27]. In addition to the simple protonation of nitrite in the stomach, there are several enzymatic pathways for conversion of systemic nitrite to NO and other bioactive nitrogen species. Hemoglobin, myoglobin, neuroglobin, xanthine oxidoreductase, aldehyde oxidase, carbonic anhydrase, and mitochondrial enzymes have all been identified with having a role in nitrite bioactivation [28] (Figure 1). However, all of these pathways are grossly inefficient along the physiological oxygen gradient with oxygen being a potent inhibitor of nitrite reduction [26, 29]. Therefore, for this system to generate enough bioactive NO, there must be sufficient nitrate and nitrite available for this inefficient reduction. A consequence of endothelial dysfunction is reduced blood and tissue levels of nitrite available for reduction [14, 30], further comprising this alternative NO pathway. Since most of the TCMs are herbal extracts, we initially thought they may be good sources of nitrite and nitrate. Also antioxidants and polyphenols have been shown to effectively reduce nitrite to NO [31]. This combination of nitrite, nitrate and polyphenols could provide then a system for repleting NO homeostasis. We recently tested and confirmed this hypothesis [32] and find that select herbal extracts contain high amounts of nitrate and also the capacity to reduce nitrite to NO. If our current paradigm is true, then restoration of NO homeostasis may be a primary target for treating and preventing CVD. A short review of this paradigm follows.

4. NO Insufficiency Is the Root Cause of CVD

CVD is a group of disorders including congestive heart failure (CHF) and ischemic heart disease that are becoming the leading cause of morbidity and mortality in the world [33, 34]. CVD can result from a quantitative or functional NO deficiency that can limit NO-dependent signal transduction pathways to the detriment of normal cellular function. NO formation by endothelial NO synthase (eNOS) plays an important role in the regulation of vasomotor tone in the pulmonary and systemic vascular beds [3537]. However, NO generation by eNOS may be rapidly depleted in ischemic conditions, since eNOS is dependent upon the availability of oxygen [38, 39]. Loss of endogenous NO activity has a number of detrimental actions, most notably, vasoconstriction, increased activity and adherence of platelets, and accumulation of inflammatory cells at sites of endothelial damage. Endothelial damage is associated with most forms of CVD. NO possesses a number of physiological properties that make it a potent cardioprotective-signaling molecule [40]. First, NO is a potent vasodilator [41], which allows for regulation of blood flow and essential perfusion of tissue as needed. Secondly, NO reversibly inhibits mitochondrial respiration [42]. The inhibition of mitochondrial respiration during an ischemia-reperfusion event such as heart attack or stroke counterintuitively leads to a decrease in mitochondrial-driven injury by extending the zone of adequate tissue cellular oxygenation away from vessels [43]. Thirdly, NO is a potent inhibitor of neutrophil adherence to vascular endothelium [44]. Neutrophil adherence is an important event initiating further leukocyte activation and superoxide radical generation, which in turn leads to injury to the endothelium and perivascular myocardium in the ischemic heart [45]. Fourth, NO also prevents platelet aggregation [46], which together with the antineutrophil actions of NO attenuates capillary plugging [47]. Finally NO inhibits apoptosis directly or indirectly by inhibiting caspase-3-like activation via a cGMP-dependent mechanisms and/or through protein S-nitrosylation [48, 49]. Without sufficient NO production, the body loses its ability to regulate and control normal vascular function. Therefore, strategies designed to enhance NO production and reduce reactive oxygen species production will likely limit injury and improve recovery from CVD or perhaps even prevent onset and progression of CVD.

5. Therapeutic Effects and Nitric Oxide Bioactivity of TCM

Traditional herbal medicines used for thousands of years in Asia and other regions have been proven effective in certain cardiovascular disorders. Some of the herbal medicines have profound NO bioactivity primarily due to the nitrate-nitrite-NO reduction pathway [32]. They contain very large amounts of nitrate/nitrite in the extracts given to patients [32]. The described benefits of these ancient medications may be attributed to their inherent nitrate/nitrite content combined with their robust nitrate/nitrite reductase activity to generate NO independent of the L-arginine-NO pathway [14, 26, 32, 50]. The first use of nitrate for treatment of patients with symptoms that appears to be angina was described in an 8th century Chinese manuscript uncovered at the Buddhist grotto of Dunhuang [51]. The patients were instructed to take Xiao Shi Xiong Huang San, hold it under the tongue for a time, and then swallow the saliva. The significance of the instructions is that under the tongue, even in a healthy mouth, nitrate-reducing bacteria convert some of the nitrate into nitrite. Therefore, if the patient follows the physician’s instructions fully, he or she will be taking nitrite, known to be effective in alleviating pain resulting from angina. Chinese physicians in traditional medicine have more recently tested the therapeutic effects of Xiao Shi Xiong Huang San (the Nitrum and Realgar Powder), one of the Dunhuang prescriptions, on angina pectoris caused by coronary heart disease. Compared to nitroglycerin, Xiao Shi Xiong Huang San showed much higher efficacy and improvement in a clinical trial of 61 patients [52]. Recently, the research results demonstrate that certain TCM increased NO release in rat vascular endothelial cells under hypoxia [53]. Purified ginsenoside Rg1 enhanced the production of NO from IFN-gamma-activated-macrophage cells RAW 264-7 [54]. Mu-Fang-Ji-Tang (TJ-36), a traditional Chinese herbal medicine, is made from four natural traditional Chinese drugs: Panax ginseng radix, Cinnamomum cassia, Sinomenum acutum, and Gypsum fibrosum, which is said to have been used for more than 1800 years to treat heart failure in China. Recent studies have shown that Mu-Fang-Ji-Tang (TJ-36) had protective effects against myocardial injury in a murine model of congestive heart failure induced by viral myocarditis [55]. Our studies have provided convincing evidence that many of these TCM contain significant amounts of nitrate and nitrite and also active nitrite reductase activity in certain herbs known to have protective or therapeutic benefits to patients with CVD (Table 1), such as the Danshen Root (radix salviae miltiorrhizae), Sanchi (radix notoginseng), and Hongshen (radix ginseng) [32]. These herbs, with specific indications for cardiovascular disease can generate NO from nitrite, and relax blood vessels. The therapeutic benefits of these herbal medicines are providing an alternative source of NO to patients that may be unable to make NO from L-arginine owing to endothelial dysfunction. There is an endogenous nitrite reductase activity in animal tissues, such as the liver and aorta, but this inherent biological capacity is low (around 1 pmoL/mg protein). The reductase activity in some of these herbal medicines may exceed that detected in the animal tissues [32]. It is estimated that the increased reductase activity may occur by orders of magnitude, almost 1000 times higher than endogenous production of NO. This would equate to 300 nmoles per day of NO from a single herbal preparation. The average NO production in the human body (70 kg) is 1.68 mmoL NO per day (based on an NO production rate of 1 μmoL/kg/h). By supplying the exogenous nitrate/nitrite and reductase activities, herbal medicines offer an alternative therapeutic strategy to combat or treat any condition related to NO insufficiency including heart disease and hypertension. Maintaining NO homeostasis requires the repletion of nitrite and nitrate through which the ability to generate NO can be restored to compensate for the inability of the endothelium to convert L-arginine to NO in coronary heart disease. This concept has recently been tested through the development of a rationally designed dietary supplement with natural products selected for their NO activity based on their nitrite, nitrate content, and an oxygen independent nitrite reductase. In a double-blinded placebo-controlled study in patients over the age of 40 with at least 3 cardiovascular risk factors, this type of technology was found to significantly restore plasma levels of nitrite and nitrate, reduce triglycerides by 27%, and modestly reduce blood pressure and C-reactive protein thereby modifying the cardiovascular risk profile of patients after only 30 days [56].

Chinese nameEnglish nameLatin nameIndicationNitrite (ng/g)Nitrate (mg/g)Nitroso (nmoL/g)NO production (pmol/mg)

DanShenDanahen RootRadix Salviae MiltiorrhizaeCAD330120001207
GuaLouSnakegourd FruitFructus TrichosanthisCAD, acute MI, Hyperlipidemia26027812046
XieBaiLongstamen Onion BulbBulbus Allii MacrostemiCAD, acute MI, Hyperlipidemia150530842134
SanChiSanchiRadix NotoginsengCAD21020697313
RuXiangFrankincenseResina OlibaniHypertension98061321072
ChiShaoRed Peony RootRadix Paeonia RubraCAD12037450255
HongShengGinsengRadix GinsengHeart failure, CAD30024376360
BingPiangBorneolBorneolum SyntheticumIncrease other herb's function for CAD or brain disease1202.99645
TianRanBingPiangBorneolCinnamomumIncrease other herb's function for CAD or brain disease1602.390875

Recent clinical studies have provided new evidence on Danshen, a commonly used herbal medicine for CVD in China, which may have a similar efficacy to the known NO donor nitroglycerin [5759]. The extract of Salviae Miltiorrhiae, or Danshen in Chinese, contains large amounts of nitrate [32]. The demonstration of beneficial effects of this herb on ischemic diseases offers an alternative avenue for the management of angina pectoris, myocardial infarction, or stroke [60, 61]. Danshen-related Chinese herbal medicines have been widely used for treatment of coronary heart disease in the East, and a clinical trial is on the way in the United States. Danshen is a routine herbal medication for acute angina pectoris. In addition, it may be effective for dyslipidemia, blood hyperviscosity syndrome, peripheral angiopathy (superficial thrombophlebitis, venous thrombosis, allergic arteriolitis), diabetes mellitus, and cirrhosis and is also used for altitude sickness. Experimental studies have shown that Danshen dilates coronary arteries, increases coronary blood flow, and scavenges free radicals in ischemic diseases, reducing cellular damage from ischemia and improving heart functions, remarkably similar to known effects of NO and nitrite [59]. However, the nitrate/nitrite reductase activity in Danshen is relatively low. Often, Danshen is mixed with other herbal products. One of which is an extract of cinnamon or borneol. Borneol is consumed excessively in China and Southeast Asian countries, particularly in a combined formula for preventing cardiovascular disease. Borneol exerts a concentration-dependent inhibitory effect on venous thrombosis [62]. The antithrombotic activity of borneol contributes to its action in combined formula for preventing cardiovascular diseases. Our recent studies have shown that although the natural form of borneol itself contains very little nitrite and nitrate, it displays a potent nitrite reductase activity [32] that when used in combination with nitrite and nitrate-rich DanShen provides the system for generating NO. Another herbal medicine made from the root of Radix ginseng may also have synergistic effects with Danshen. Ginseng contains modest amounts of nitrate but has stronger reductase activity [32]. Therefore, this may explain the mechanism behind the theory of synergy of specific combination of herbs.

6. Effects of TCM on L-Arginine/eNOS/NO Signaling Pathway

Some TCM may regulate NO production by exerting regulatory effects on the L-arginine/eNOS/NO signaling pathway. Puerarin is a major active ingredient extracted from the traditional Chinese medicine Ge-gen (Radix Puerariae, RP). It has long been used to treat cardiovascular diseases including coronary artery diseases (CAD), arrhythmia, and hypertension. Recent studies have shown that puerarin increases serum nitrite concentrations in rats with myocardial ischemia through the induction of protein expression and activation of eNOS and through Akt/PKB phosphorylation [63]. Tongxinluo (TXL), a mixture of traditional Chinese medicines, can attenuate the no-reflow and ischemia-reperfusion injury in an infarct animal model [64, 65]. TXL is composed of Radix ginseng, Buthus martensii, Hirudo, Eupolyphaga seu steleophaga, Scolopendra subspinipes, Periostracum cicadae, Radix paeoniae rubra, Semen ziziphi spinosae, Lignum dalbergiae odoriferae, Lignum santali albi, and Borneolum syntheticum. Owing to its efficacy and minimal adverse effects, TXL has been widely used in China to treat patients with acute coronary syndrome. In a 90-minute ischemia and 3-hour reperfusion model, miniature pigs were randomly assigned to treatment with TXL (gavaged 1 hour prior to ischemia); TXL plus H-89 (protein kinase-A inhibitor intravenously infused before ischemia); or TXL plus N(omega)-nitro-L-arginine (L-NNA; an eNOS inhibitor, intravenously administered prior to ischemia). The results of this study demonstrate that TXL treatment can decrease creatine kinase elevation, improve coronary flow, and reduce infarct size. The effects of TXL may be partially abolished by H-89 or completely reversed by L-NNA. In addition, TXL treatment can elevate the kinase activity and expression, evidenced by expression of Thr198 phosphorated-PKA, Ser1179 phosphorated-eNOS (p-eNOS), and Ser635 p-eNOS in the ischemic myocardium. Addition of H-89 diminishes the TXL activities. Thus, pretreatment with a single low loading dose of TXL 1 hour before ischemia reduces the myocardial no-reflow phenomenon and ischemia-reperfusion injury by upregulating the phosphorylation of eNOS at Ser1179 and Ser635, and this effect is partially mediated by the PKA pathway [64]. Recent studies also have shown that Salvianolic acid B (Sal B) and Tanshinone IIA (Tan IIA) are two of the major components in Danshen, have cardioprotective effects in an in vivo myocardial infarction model of C57 mice, have vasodilator action in an ex vivo microartery system through the endothelial nitric oxide synthase (eNOS)/nitric oxide pathway, and are involved in the regulation of the L-arginine/eNOS/NO pathways in human umbilical vein endothelial cells (HUVECs). Both Sal B and Tan IIA inhibited cardiac hypertrophy and infarction sizes and improved cardiac function at 4 weeks after induction of infarction. Furthermore, an eNOS inhibitor (L-NAME) obliterated the observed effects. Sal B and Tan IIA mediated vasodilatation in mice coronaries ex vivo, the effect of which was decreased with either L-NAME or PI3K inhibitor (LY294002). In addition, Sal B and Tan IIA-induced vasodilatation was observed ex vivo in the microvessels of eNOS−/− mice. Sal B and Tan IIA also stimulated eNOS phosphorylation in a concentration- and time-dependent manner in the HUVEC culture, which was diminished by LY294002. In addition, Sal B and Tan IIA were found to stimulate the phosphorylation of AMPK (Thr(172)) and Akt (Ser(473)), while compound C significantly decreased the phosphorylation of Akt (Ser(473)) mediated by both. Finally, Sal B and Tan IIA were found to induce [(3)H]-L-arginine uptake and increase the CAT-1 and CAT-2B mRNA levels in HUVEC culture [66]. It appears that select TCM herbs alone and in combination can restore NO homeostasis both through an endothelium dependent manner by activating the L-arginine pathway and through an endothelium-independent manner via the nitrate-nitrite-NO pathway that may overcome endothelial dysfunction.

7. Effects of CAM on Oxidative Stress and Preservation of NO Activity

In several chronic diseases, free radicals are by-products of abnormal body metabolism and are important factors for late complications and secondary disease especially those related to NO and endothelial dysfunction [67]. There is increasing evidence that in certain pathologic states the increased production and/or ineffective scavenging of reactive oxygen species (ROS) may play a critical role. Medicinal plants are a source for a wide variety of natural antioxidants [68] and my exhibit their effects via several proposed mechanisms, including inhibition of the activities of cyclooxygenase-2 (COX-2) and nuclear factor-Kappa B (NF- B), inhibition of angiogenesis, and activation of Nrf2-mediated antioxidant signaling [69], all known to interface with the NO pathway. Dang Gui has been shown to hold anti-inflammatory properties and antioxidant activities, especially when used concurrently with other herbs [70]. Dietz and colleagues have reported that the major lipophilic constituent of Dang Gui, Z-ligustilide, reduces oxidative stress through upregulation of antioxidant enzymes such as NQO1, an Nrf2 pathway gene [71]. Also, A. sinensis can protect against oxidant injury through elevated glutathione synthesis whose rate limiting step is regulated by the Nrf2-regulated gene γ-GCS [72]. Of the different components in Dan Shen, tanshinone IIA has been identified with the most potent antioxidant activity and cytotoxic properties by inducing apoptosis and differentiation in various human cancer cell lines [73]. Tanshinone IIA also displays antioxidant protection against reactive oxygen species (ROS) induced oxidative stress through stress-activated kinases JNKs and p38 MAPK and by an increase in scavenging of oxygen free radicals [74]. Drinking tea is a tradition that began in ancient China over 5000 years ago. Green tea from the leaves of Camellia sinensis is the second most consumed beverage in the world, after water. It is a well-studied herb for its effectiveness in chemoprevention, cancer therapy, and other benefits to overall health. The main components of green tea are polyphenols, known as catechins, which account for 30–42% of the solid weight in green tea leaves. The most abundant polyphenol in green tea is (−)-epigallocatechin-3-gallate (EGCG), which is also the most commonly studied green tea component [75]. EGCG contributes to 10–50% of the total polyphenol contents in green tea and appears to possess the strongest antioxidant activity, about 25–100 fold more potent than vitamins C and E [75]. Reducing oxidative stress and promoting endogenous antioxidant enzymatic defense systems very likely provides an additional benefit of traditional medicines. These antioxidants defenses will enhance endogenous NO production by keeping essential cofactors such as BH4 from becoming oxidized and also preserve and prolong NO activity once it is produced by preventing its scavenging by oxygen radicals.

8. Conclusion

Taken together, the NO signaling pathway plays an important role in the therapeutic effect of many CAMs used for cardiovascular disease (Figure 2). The NO donor-like herbs may serve as an alternative source of nitrate and nitrite or other NO-donors. They contain high activities of nitrite reductase that converts the inorganic anion into NO, which, in turn, relaxes blood vessels and prevents thrombosis. There are also some TCM which contain regulatory factors that influence the expression and activity of eNOS (Figure 2) and may interact with endogenous factors that modulate L-arginine/eNOS/NO signaling pathway. Modern research is providing more evidence to understand specific activity of CAMs that will hopefully provide a mechanistic understanding of their clinical efficacy and allow for better combination of different herbs. However, currently the use of CAM is influenced by legal restrictions, with shifts towards increasing regulation and formal recognition of CAM as means to treat or prevent disease. Further investigation and research are warranted in terms of the functional mechanisms, biosafety, and large-scale clinical trials to firmly establish the efficacy of many of these approaches in the prevention and treatment of illnesses.


  1. P. Davidson, K. Hancock, D. Leung et al., “Traditional Chinese Medicine and heart disease: what does Western medicine and nursing science know about it?” European Journal of Cardiovascular Nursing, vol. 2, no. 3, pp. 171–181, 2003. View at: Publisher Site | Google Scholar
  2. C. N. Gillis, “Panax ginseng pharmacology: a nitric oxide link?” Biochemical Pharmacology, vol. 54, no. 1, pp. 1–8, 1997. View at: Publisher Site | Google Scholar
  3. X. Chen, “Cardiovascular protection by ginsenosides and their nitric oxide releasing action,” Clinical and Experimental Pharmacology and Physiology, vol. 23, no. 8, pp. 728–732, 1996. View at: Google Scholar
  4. P. Barnes, E. Powell-Griner, K. E, McFann, and R. Nahin, CDC Advance Data Report #343. Complementary and Alternative Medicine Use Among Adults: United States, 2002.
  5. D. J. Stuehr, “Structure-function aspects in the nitric oxide synthases,” Annual Review of Pharmacology and Toxicology, vol. 37, pp. 339–359, 1997. View at: Google Scholar
  6. R. Rafikov, F. V. Fonseca, S. Kumar et al., “eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity,” Journal of Endocrinology, vol. 210, no. 3, pp. 271–284, 2011. View at: Publisher Site | Google Scholar
  7. L. J. Ignarro, C. Napoli, and J. Loscalzo, “Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview,” Circulation Research, vol. 90, no. 1, pp. 21–28, 2002. View at: Publisher Site | Google Scholar
  8. K. Egashira, T. Inou, Y. Hirooka et al., “Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans,” Circulation, vol. 88, no. 1, pp. 77–81, 1993. View at: Google Scholar
  9. M. Gerhard, M. A. Roddy, S. J. Creager, and M. A. Creager, “Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans,” Hypertension, vol. 27, no. 4, pp. 849–853, 1996. View at: Google Scholar
  10. S. Taddei, A. Virdis, L. Ghiadoni et al., “Age-related reduction of NO availability and oxidative stress in humans,” Hypertension, vol. 38, no. 2, pp. 274–279, 2001. View at: Google Scholar
  11. M. T. Gladwin, A. N. Schechter, D. B. Kim-Shapiro et al., “The emerging biology of the nitrite anion,” Nature Chemical Biology, vol. 1, no. 6, pp. 308–314, 2005. View at: Publisher Site | Google Scholar
  12. N. S. Bryan, “Nitrite in nitric oxide biology: cause or consequence?. A systems-based review,” Free Radical Biology and Medicine, vol. 41, no. 5, pp. 691–701, 2006. View at: Publisher Site | Google Scholar
  13. N. S. Bryan, J. W. Calvert, J. W. Elrod, S. Gundewar, Y. J. Sang, and D. J. Lefer, “Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 48, pp. 19144–19149, 2007. View at: Publisher Site | Google Scholar
  14. N. S. Bryan, J. W. Calvert, S. Gundewar, and D. J. Lefer, “Dietary nitrite restores NO homeostasis and is cardioprotective in endothelial nitric oxide synthase-deficient mice,” Free Radical Biology and Medicine, vol. 45, no. 4, pp. 468–474, 2008. View at: Publisher Site | Google Scholar
  15. J. Zhan, A. Nakao, R. Sugimoto et al., “Orally administered nitrite attenuates cardiac allograft rejection in rats,” Surgery, vol. 146, no. 2, pp. 155–165, 2009. View at: Publisher Site | Google Scholar
  16. N. G. Hord, Y. Tang, and N. S. Bryan, “Food sources of nitrates and nitrites: the physiologic context for potential health benefits,” American Journal of Clinical Nutrition, vol. 90, no. 1, pp. 1–10, 2009. View at: Publisher Site | Google Scholar
  17. J. O. Lundberg, M. T. Gladwin, A. Ahluwalia et al., “Nitrate and nitrite in biology, nutrition and therapeutics,” Nature Chemical Biology, vol. 5, no. 12, pp. 865–869, 2009. View at: Publisher Site | Google Scholar
  18. J. O. Lundberg, E. Weitzberg, and M. T. Gladwin, “The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics,” Nature Reviews Drug Discovery, vol. 7, no. 2, pp. 156–167, 2008. View at: Publisher Site | Google Scholar
  19. F. J. Larsen, B. Ekblom, K. Sahlin, J. O. Lundberg, and E. Weitzberg, “Effects of dietary nitrate on blood pressure in healthy volunteers,” The New England Journal of Medicine, vol. 355, no. 26, pp. 2792–2793, 2006. View at: Publisher Site | Google Scholar
  20. A. J. Webb, N. Patel, S. Loukogeorgakis et al., “Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite,” Hypertension, vol. 51, no. 3, pp. 784–790, 2008. View at: Publisher Site | Google Scholar
  21. T. Sobko, C. Marcus, M. Govoni, and S. Kamiya, “Dietary nitrate in Japanese traditional foods lowers diastolic blood pressure in healthy volunteers,” Nitric Oxide, vol. 22, no. 2, pp. 136–140, 2010. View at: Publisher Site | Google Scholar
  22. W. C. Willett, “Diet and health: what should we eat?” Science, vol. 264, no. 5158, pp. 532–537, 1994. View at: Google Scholar
  23. K. J. Joshipura, F. B. Hu, J. E. Manson et al., “The effect of fruit and vegetable intake on risk for coronary heart disease,” Annals of Internal Medicine, vol. 134, no. 12, pp. 1106–1114, 2001. View at: Google Scholar
  24. K. J. Joshipura, A. Ascherio, J. E. Manson et al., “Fruit and vegetable intake in relation to risk of ischemic stroke,” JAMA, vol. 282, no. 13, pp. 1233–1239, 1999. View at: Publisher Site | Google Scholar
  25. J. O. Lundberg, E. Weitzberg, J. A. Cole, and N. Benjamin, “Nitrate, bacteria and human health,” Nature Reviews Microbiology, vol. 2, no. 7, pp. 593–602, 2004. View at: Publisher Site | Google Scholar
  26. M. Feelisch, B. O. Fernandez, N. S. Bryan et al., “Tissue processing of nitrite in hypoxia: an intricate interplay of nitric oxide-generating and -scavenging systems,” The Journal of Biological Chemistry, vol. 283, no. 49, pp. 33927–33934, 2008. View at: Publisher Site | Google Scholar
  27. H. Björne, J. Petersson, M. Phillipson, E. Weitzberg, L. Holm, and J. O. Lundberg, “Nitrite in saliva increases gastric mucosal blood flow and mucus thickness,” The Journal of Clinical Investigation, vol. 113, no. 1, pp. 106–114, 2004. View at: Publisher Site | Google Scholar
  28. E. Weitzberg, M. Hezel, and J. O. Lundberg, “Nitrate-nitrite-nitric oxide pathway: implications for anesthesiology and intensive care,” Anesthesiology, vol. 113, no. 6, pp. 1460–1475, 2010. View at: Publisher Site | Google Scholar
  29. N. S. Bryan, B. O. Fernandez, S. M. Bauer et al., “Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues,” Nature Chemical Biology, vol. 1, no. 5, pp. 290–297, 2005. View at: Publisher Site | Google Scholar
  30. P. Kleinbongard, A. Dejam, T. Lauer et al., “Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans,” Free Radical Biology and Medicine, vol. 40, no. 2, pp. 295–302, 2006. View at: Publisher Site | Google Scholar
  31. B. Gago, J. O. Lundberg, R. M. Barbosa, and J. Laranjinha, “Red wine-dependent reduction of nitrite to nitric oxide in the stomach,” Free Radical Biology and Medicine, vol. 43, no. 9, pp. 1233–1242, 2007. View at: Publisher Site | Google Scholar
  32. Y. Tang, H. Garg, Y. J. Geng, and N. S. Bryan, “Nitric oxide bioactivity of traditional Chinese medicines used for cardiovascular indications,” Free Radical Biology and Medicine, vol. 47, no. 6, pp. 835–840, 2009. View at: Publisher Site | Google Scholar
  33. D. Yach, C. Hawkes, C. L. Gould, and K. J. Hofman, “The global burden of chronic diseases: overcoming impediments to prevention and control,” JAMA, vol. 291, no. 21, pp. 2616–2622, 2004. View at: Publisher Site | Google Scholar
  34. C. J. L. Murray and A. D. Lopez, “Alternative projections of mortality and disability by cause 1990–2020: global Burden of Disease Study,” The Lancet, vol. 349, no. 9064, pp. 1498–1504, 1997. View at: Publisher Site | Google Scholar
  35. T. J. McMahon, J. S. Hood, J. A. Bellan, and P. J. Kadowitz, “N(ω)-nitro-L-arginine methyl ester selectively inhibits pulmonary vasodilator responses to acetylcholine and bradykinin,” Journal of Applied Physiology, vol. 71, no. 5, pp. 2026–2031, 1991. View at: Google Scholar
  36. T. J. McMahon, J. S. Hood, and P. J. Kadowitz, “Pulmonary vasodilator response to vagal stimulation is blocked by N(ω)-nitro-L-arginine methyl ester in the cat,” Circulation Research, vol. 70, no. 2, pp. 364–369, 1992. View at: Google Scholar
  37. D. D. Rees, R. M. J. Palmer, R. Schulz, H. F. Hodson, and S. Moncada, “Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo,” British Journal of Pharmacology, vol. 101, no. 3, pp. 746–752, 1990. View at: Google Scholar
  38. A. J. North, K. S. Lau, T. S. Brannon et al., “Oxygen upregulates nitric oxide synthase gene expression in ovine fetal pulmonary artery endothelial cells,” American Journal of Physiology, vol. 270, no. 4, pp. L643–L649, 1996. View at: Google Scholar
  39. N. Kim, Y. Vardi, H. Padma-Nathan, J. Daley, I. Goldstein, and I. S. De Tejada, “Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection,” The Journal of Clinical Investigation, vol. 91, no. 2, pp. 437–442, 1993. View at: Google Scholar
  40. D. J. Lefer, “Myocardial protective actions of nitric oxide donors after myocardial ischemia and reperfusion,” New Horizons, vol. 3, no. 1, pp. 105–112, 1995. View at: Google Scholar
  41. G. Johnson, P. S. Tsao, and A. M. Lefer, “Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion,” Critical Care Medicine, vol. 19, no. 2, pp. 244–252, 1991. View at: Google Scholar
  42. K. E. Loke, S. K. Laycock, S. Mital et al., “Nitric oxide modulates mitochondrial respiration in failing human heart,” Circulation, vol. 100, no. 12, pp. 1291–1297, 1999. View at: Google Scholar
  43. D. D. Thomas, X. Liu, S. P. Kantrow, and J. R. Lancaster, “The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 1, pp. 355–360, 2001. View at: Google Scholar
  44. X. I. Ma, A. S. Weyrich, D. J. Lefer, and A. M. Lefer, “Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium,” Circulation Research, vol. 72, no. 2, pp. 403–412, 1993. View at: Google Scholar
  45. A. J. Palazzo, S. P. Jones, W. G. Girod, D. C. Anderson, D. N. Granger, and D. J. Lefer, “Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice,” American Journal of Physiology, vol. 275, no. 6, part 2, pp. H2300–H2307, 1998. View at: Google Scholar
  46. U. Walter and S. Gambaryan, “Roles of cGMP/cGMP-dependent protein kinase in platelet activation,” Blood, vol. 104, no. 8, article 2609, 2004. View at: Publisher Site | Google Scholar
  47. J. W. Calvert and D. J. Lefer, “Statin therapy and myocardial no-reflow,” British Journal of Pharmacology, vol. 149, no. 3, pp. 229–231, 2006. View at: Publisher Site | Google Scholar
  48. J. Li, C. A. Bombeck, S. Yang, Y. M. Kim, and T. R. Billiar, “Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes,” The Journal of Biological Chemistry, vol. 274, no. 24, pp. 17325–17333, 1999. View at: Publisher Site | Google Scholar
  49. Y. M. Kim, R. V. Talanian, and T. R. Billiar, “Nitric oxide inhibits apoptosis by preventing increases in caspase-3- like activity via two distinct mechanisms,” The Journal of Biological Chemistry, vol. 272, no. 49, pp. 31138–31148, 1997. View at: Publisher Site | Google Scholar
  50. J. O. Lundberg and M. Govoni, “Inorganic nitrate is a possible source for systemic generation of nitric oxide,” Free Radical Biology and Medicine, vol. 37, no. 3, pp. 395–400, 2004. View at: Publisher Site | Google Scholar
  51. A. R. Butler and M. Feelisch, “Therapeutic uses of inorganic nitrite and nitrate: from the past to the future,” Circulation, vol. 117, no. 16, pp. 2151–2159, 2008. View at: Publisher Site | Google Scholar
  52. X. Liu, H. Ma, C. Li et al., “Sixty-one cases of angina pectoris due to coronary heart disease treated by external use of the Paste of Nitrum and Realgar Powder on Zhiyang (GV 9),” Journal of Traditional Chinese Medicine, vol. 22, no. 4, pp. 243–246, 2002. View at: Google Scholar
  53. P. Liu, Y. C. Ge, T. S. Ma, H. J. Ren, Y. J. Xu, and D. M. Xu, “Effects of the extracts from Decoction for resuscitation and its component herbs on PGI2, TXA2 and NO release from rat vascular endothelial cells under hypoxia in vitro,” Zhongguo Zhongyao Zazhi, vol. 29, no. 10, pp. 988–992, 2004. View at: Google Scholar
  54. Z. H. Fan, K. Isobe, K. Kiuchi, and I. Nakashima, “Enhancement of nitric oxide production from activated macrophages by a purified form of ginsenoside (Rg1),” The American journal of Chinese medicine, vol. 23, no. 3-4, pp. 279–287, 1995. View at: Google Scholar
  55. W. Z. Wang, A. Matsumori, Y. Matoba et al., “Protective effects of Mu-Fang-Ji-Tang against myocardial injury in a murine model of congestive heart failure induced by viral myocarditis,” Life Sciences, vol. 62, no. 13, pp. 1139–1146, 1998. View at: Publisher Site | Google Scholar
  56. J. Zand, F. Lanza, H. K. Garg, and N. S. Bryan, “All-natural nitrite and nitrate containing dietary supplement promotes nitric oxide production and reduces triglycerides in humans,” Nutrition Research, vol. 31, no. 4, pp. 262–269, 2011. View at: Publisher Site | Google Scholar
  57. F. F. Y. Lam, J. H. K. Yeung, K. M. Chan, and P. M. Y. Or, “Mechanisms of the dilator action of cryptotanshinone on rat coronary artery,” European Journal of Pharmacology, vol. 578, no. 2-3, pp. 253–260, 2008. View at: Publisher Site | Google Scholar
  58. F. Y. Lam, S. C. W. Ng, J. H. Y. Cheung, and J. H. K. Yeung, “Mechanisms of the vasorelaxant effect of Danshen (Salvia miltiorrhiza) in rat knee joints,” Journal of Ethnopharmacology, vol. 104, no. 3, pp. 336–344, 2006. View at: Publisher Site | Google Scholar
  59. L. Zhou, Z. Zuo, and M. S. S. Chow, “Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use,” Journal of Clinical Pharmacology, vol. 45, no. 12, pp. 1345–1359, 2005. View at: Publisher Site | Google Scholar
  60. M. H. Li, J. M. Chen, Y. Peng, Q. Wu, and P. G. Xiao, “Investigation of Danshen and related medicinal plants in China,” Journal of Ethnopharmacology, vol. 120, no. 3, pp. 419–426, 2008. View at: Publisher Site | Google Scholar
  61. W. Li, Z. W. Li, J. P. Han, X. X. Li, J. Gao, and C. X. Liu, “Determination and pharmacokinetics of danshensu in rat plasma after oral administration of danshen extract using liquid chromatography/tandem mass spectrometry,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 33, no. 1, pp. 9–16, 2008. View at: Google Scholar
  62. Y. H. Li, X. P. Sun, Y. Q. Zhang, and N. S. Wang, “The antithrombotic effect of Borneol related to its anticoagulant property,” American Journal of Chinese Medicine, vol. 36, no. 4, pp. 719–727, 2008. View at: Publisher Site | Google Scholar
  63. S. Y. Zhang, G. Chen, P. F. Wei et al., “The effect of puerarin on serum nitric oxide concentration and myocardial eNOS expression in rats with myocardial infarction,” Journal of Asian natural products research, vol. 10, no. 3-4, pp. 373–381, 2008. View at: Google Scholar
  64. X. D. Li, Y. J. Yang, Y. J. Geng et al., “Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway,” American Journal of Physiology, vol. 299, no. 4, pp. H1255–H1261, 2010. View at: Publisher Site | Google Scholar
  65. Y. T. Cheng, Y. J. Yang, H. T. Zhang et al., “Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism,” Chinese Medical Journal, vol. 122, no. 13, pp. 1529–1538, 2009. View at: Publisher Site | Google Scholar
  66. C. Pan, L. Lou, Y. Huo et al., “Salvianolic acid B and Tanshinone IIA attenuate myocardial ischemia injury in mice by no production through multiple pathways,” Therapeutic Advances in Cardiovascular Disease, vol. 5, no. 2, pp. 99–111, 2011. View at: Publisher Site | Google Scholar
  67. J. Loscalzo, “Oxidative stress in endothelial cell dysfunction and thrombosis,” Pathophysiology of Haemostasis and Thrombosis, vol. 32, no. 5-6, pp. 359–360, 2002. View at: Publisher Site | Google Scholar
  68. S. Hasani-Ranjbar, B. Larijani, and M. Abdollahi, “A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases,” Inflammation and Allergy—Drug Targets, vol. 8, no. 1, pp. 2–10, 2009. View at: Publisher Site | Google Scholar
  69. S. Wang, S. Penchala, S. Prabhu, J. Wang, and Y. Huang, “Molecular basis of traditional chinese medicine in cancer chemoprevention,” Current Drug Discovery Technologies, vol. 7, no. 1, pp. 67–75, 2010. View at: Publisher Site | Google Scholar
  70. Q. Chu, K. Hashimoto, K. Satoh, Q. Wang, and H. Sakagami, “Effect of three herbal extracts on NO and PGE2 production by activated mouse macrophage-like cells,” In Vivo, vol. 23, no. 4, pp. 537–544, 2009. View at: Google Scholar
  71. B. M. Dietz, D. Liu, G. K. Hagos et al., “Angelica sinensis and its alkylphthalides induce the detoxification enzyme NAD(P)H: quinone oxidoreductase 1 by alkylating keap1,” Chemical Research in Toxicology, vol. 21, no. 10, pp. 1939–1948, 2008. View at: Publisher Site | Google Scholar
  72. Y. C. Po, Y. L. Hoi, A. H. Y. Siu et al., “Dang-Gui Buxue Tang Protects against oxidant injury by enhancing cellular glutathione in H9c2 cells: role of glutathione synthesis and regeneration,” Planta Medica, vol. 73, no. 2, pp. 134–141, 2007. View at: Publisher Site | Google Scholar
  73. W. L. Wu, W. L. Chang, and C. F. Chen, “Cytotoxic activities of tanshinones against human carcinoma cell lines,” American Journal of Chinese Medicine, vol. 19, no. 3-4, pp. 207–216, 1991. View at: Google Scholar
  74. R. Yang, A. Liu, X. Ma, L. Li, D. Su, and J. Liu, “Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation,” Journal of Cardiovascular Pharmacology, vol. 51, no. 4, pp. 396–401, 2008. View at: Publisher Site | Google Scholar
  75. N. Khan and H. Mukhtar, “Multitargeted therapy of cancer by green tea polyphenols,” Cancer Letters, vol. 269, no. 2, pp. 269–280, 2008. View at: Publisher Site | Google Scholar

Copyright © 2012 Hong Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

4827 Views | 1068 Downloads | 9 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.